Calcium Channel Blocker Drugs Market, by Drug Class (Benzothizepine, Dihydropyridine and Phenylalkylamine), by Disease Indication (Hypertension, Chest Pain, Arrhythmias, and Others (Blood vessel conditions, Coronary Artery Disease etc.)), by Distribution

Calcium Channel Blocker Drugs Market, by Drug Class (Benzothizepine, Dihydropyridine and Phenylalkylamine), by Disease Indication (Hypertension, Chest Pain, Arrhythmias, and Others (Blood vessel conditions, Coronary Artery Disease etc.)), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.

Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ’s function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease – this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.

Market Dynamics

Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.

For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.

Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period

For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.

Key features of the study:

• This report provides an in-depth analysis of the global calcium channel blocker drugs market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global calcium channel blocker drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global calcium channel blocker drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcium channel blocker drugs market

Detailed Segmentation:

• Global Calcium Channel Blocker Drugs Market, By Drug Class:
• Benzothizepine
• Dihydropyridine
• Phenylalkylamine
• Global Calcium channel blocker drugs market, By Disease Indication:
• Hypertension
• Chest Pain
• Arrhythmias
• Others (Blood vessel conditions, Coronary Artery Disease etc.)
• Global Calcium Channel Blocker Drugs Market, By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Global Calcium Channel Blocker Drugs Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• U.K.
• Germany
• France
• Spain
• Italy
• Russia
• Rest Of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Bausch Health*
• Company Overview
• Disease Indication Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd
• Lupin
• Arbor Pharmaceuticals
• GlaxoSmithKline Plc
• Biopharma
• Sofgen Pharmaceuticals
• Glenmark Pharmaceuticals Inc
• Amneal Pharmaceuticals
• Sun Pharmaceutical Industries Ltd,
• Novartis AG
• Zydus Cadila
• Pfizer Inc,

“*” marked represents similar segmentation in other categories in the respective section.